Thanks. I did note last year FDA has already granted BENDEKA Orphan Drug Designations for both CLL and indolent B-cell NHL.
Making the designation exclusive, hopefully should not be an issue as current SOC esp in indolent B-cell NHL, if I am not mistaken, is hodgepodge of chemo drugs.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.